Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


21.11.2022

4 Aliment Pharmacol Ther
1 Am J Surg
3 BMC Gastroenterol
2 Clin Gastroenterol Hepatol
5 Dig Dis Sci
1 Dis Colon Rectum
2 Gastroenterol Hepatol
2 Inflamm Bowel Dis
1 J Crohns Colitis
1 J Gastroenterol
1 Lancet Gastroenterol Hepatol
7 Scand J Gastroenterol
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
    Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
    PubMed         Abstract available

  2. YUAN S, Sun Y, Tan X, Geng J, et al
    Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
    PubMed         Abstract available

  3. VUIJK SA, de Ridder L
    Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56.
    PubMed        

  4. KULYK A, Shafer LA, Graff LA, Stone J, et al
    Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
    Aliment Pharmacol Ther. 2022;56.
    PubMed         Abstract available


    Am J Surg

  5. CONNELLY TM, Holubar SD, Clancy C, Cheong JY, et al
    Outcomes of clostridioides difficile infection on inflammatory bowel disease patients undergoing colonic resection: A propensity score weighted NSQIP analysis.
    Am J Surg. 2022 Nov 2. pii: S0002-9610(22)00708.
    PubMed         Abstract available


    BMC Gastroenterol

  6. JOHNSEN KM, Florholmen J, Moe OK, Gundersen M, et al
    Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
    BMC Gastroenterol. 2022;22:459.
    PubMed         Abstract available

  7. GOLL R, Moe OK, Johnsen KM, Meyer R, et al
    Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    BMC Gastroenterol. 2022;22:464.
    PubMed         Abstract available

  8. XU Z, Chen JJ, Mei Q, Li Y, et al
    Expression of 5-hydroxytryptamine 7 receptor in intestinal mucosa correlates with the degree of intestinal inflammation in Crohn's disease.
    BMC Gastroenterol. 2022;22:457.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  9. PAPAMICHAEL K, Vande Casteele N, Abraham BP, Ritter T, et al
    Prior antibodies to infliximab or adalimumab are related to immunogenicity to vedolizumab in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 10. pii: S1542-3565(22)01053.
    PubMed        

  10. ALAYO Q, Deepak P
    Reply to Letter to the Editor: Inflammatory Bowel Disease and Incident Acute Arterial Events in the United Kingdom Biobank.
    Clin Gastroenterol Hepatol. 2022 Nov 12. pii: S1542-3565(22)01052.
    PubMed        


    Dig Dis Sci

  11. MONGARDINI FM
    Author Spotlight: Federico Maria Mongardini.
    Dig Dis Sci. 2022;67:5433.
    PubMed        

  12. TURBAYNE AK, Sparrow MP
    Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.
    Dig Dis Sci. 2022;67:5382-5391.
    PubMed         Abstract available

  13. PEYRIN-BIROULET L, Bouguen G, Laharie D, Pellet G, et al
    Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study.
    Dig Dis Sci. 2022;67:5637-5646.
    PubMed         Abstract available

  14. KAAZAN P, Tan Z, Maiyani P, Mickenbecker M, et al
    Weight and BMI Patterns in a Biologicals-Treated IBD Cohort.
    Dig Dis Sci. 2022;67:5628-5636.
    PubMed         Abstract available

  15. LEE KE, Lim F, Faye AS, Shen B, et al
    Endoscopic Balloon Dilation Is Cost-Effective for Crohn's Disease Strictures.
    Dig Dis Sci. 2022;67:5462-5471.
    PubMed         Abstract available


    Dis Colon Rectum

  16. LI S, Ding C, Zhu F, Wang Z, et al
    Ileoanal Pouch Syndrome Is Common and Associated With Significant Disability in Patients With Ulcerative Colitis Undergoing IPAA.
    Dis Colon Rectum. 2022;65:1503-1513.
    PubMed         Abstract available


    Gastroenterol Hepatol

  17. PARRA-IZQUIERDO V, Frias-Ordonez JS, Marquez JR, Juliao-Banos F, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Gastroenterol Hepatol. 2022 Nov 10. pii: S0210-5705(22)00266.
    PubMed         Abstract available

  18. QUERA R, Nunez P, Sicilia B, Flores L, et al
    Corticosteroids in Inflammatory Bowel Disease: Are they still a therapeutic option?
    Gastroenterol Hepatol. 2022 Nov 11. pii: S0210-5705(22)00263.
    PubMed         Abstract available


    Inflamm Bowel Dis


  19. Correction to: Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2022 Nov 18. pii: 6832530. doi: 10.1093.
    PubMed        

  20. POLAT G, Kani HT, Ergenc I, Ozen Alahdab Y, et al
    Improving the Computer-Aided Estimation of Ulcerative Colitis Severity According to Mayo Endoscopic Score by Using Regression-Based Deep Learning.
    Inflamm Bowel Dis. 2022 Nov 16. pii: 6830946. doi: 10.1093.
    PubMed         Abstract available


    J Crohns Colitis

  21. KORI M, Zamir Y, Yermiyahu SO, Ainbinder I, et al
    The association of Inflammatory Bowel Disease with Celiac Disease and Celiac Autoimmunity in children and adults: A nationwide study from the epi-IIRN.
    J Crohns Colitis. 2022 Nov 17. pii: 6832168. doi: 10.1093.
    PubMed         Abstract available


    J Gastroenterol

  22. ANDOH A, Nishida A
    Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease.
    J Gastroenterol. 2022 Nov 14. pii: 10.1007/s00535-022-01936.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  23. ALLEGRETTI JR
    Should faecal microbiota transplantation be used earlier in the treatment framework?
    Lancet Gastroenterol Hepatol. 2022;7:1062-1063.
    PubMed        


    Scand J Gastroenterol

  24. ERONEN H, Oksanen P, Jussila A, Huhtala H, et al
    Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy.
    Scand J Gastroenterol. 2022 Nov 17:1-6. doi: 10.1080/00365521.2022.2143727.
    PubMed         Abstract available

  25. KRARUP AL, Larsen L, Nayeb AB, Grontved S, et al
    Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
    Scand J Gastroenterol. 2022 Nov 10:1-6. doi: 10.1080/00365521.2022.2143726.
    PubMed         Abstract available

  26. GOETGEBUER RL, van der Woude CJ, Bakker L, van der Eijk AA, et al
    The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists.
    Scand J Gastroenterol. 2022;57:1321-1326.
    PubMed         Abstract available

  27. YU L, Zhang MM, Hou JG
    Molecular and cellular pathways in colorectal cancer: apoptosis, autophagy and inflammation as key players.
    Scand J Gastroenterol. 2022;57:1279-1290.
    PubMed         Abstract available

  28. BLESL A, Petritsch W, Binder L, Furst S, et al
    Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Scand J Gastroenterol. 2022;57:1327-1330.
    PubMed         Abstract available

  29. BRUNET-HOUDARD S, Monmousseau F, Berthon G, Des Garets V, et al
    How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
    Scand J Gastroenterol. 2022;57:1312-1320.
    PubMed         Abstract available

  30. LEE CH, Huang S, Hsu P, Leong RW, et al
    Low-dose IL-2 may enhance the effect of vedolizumab.
    Scand J Gastroenterol. 2022;57:1404-1405.
    PubMed        


    Z Gastroenterol

  31. WEBER K, Zeissig Y, Haag C, Schmelz R, et al
    [Chronic or severe enteropathy and immunodeficiency: be prepared for a rara avis].
    Z Gastroenterol. 2022;60:1668-1677.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: